The Georgian Health Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Georgian Health Digest.

October 2025

Mo	Tu	We	Th	Fr	Sa	Su
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

November 2025

Mo	Tu	We	Th	Fr	Sa	Su
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

December 2025

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Press releases published on December 8, 2025

December 8, 2025

Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026

GlobeNewswire

December 8, 2025

Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD

GlobeNewswire

December 8, 2025

Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

GlobeNewswire

December 8, 2025

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

GlobeNewswire

December 8, 2025

Monaghan Medical Earns 2025 AARC Zenith Award — A Decade of Trust and Innovation Recognized by Respiratory Care Professionals

GlobeNewswire

December 8, 2025

Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

GlobeNewswire

December 8, 2025

Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply

GlobeNewswire

December 8, 2025

MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

GlobeNewswire

December 8, 2025

Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01

GlobeNewswire

December 8, 2025

AskForHelpToday.ca Launches in New Brunswick, Improving Access to Mental Health Care

GlobeNewswire

December 8, 2025

AskForHelpToday.ca est lancé au Nouveau-Brunswick, améliorant l’accès aux soins en santé mentale

GlobeNewswire

December 8, 2025

Geneva College of Longevity Science and DrVibe.ai Launch the GCLS AI Academy for Longevity Sciences

GlobeNewswire

December 8, 2025

Pan Cancer T Secures EUR 10 Million to Advance First-in-Human Trial of Novel TCR-T Cell Therapy for Triple-Negative Breast Cancer

GlobeNewswire

December 8, 2025

Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue™, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia

GlobeNewswire

December 8, 2025

FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA HIDRADENITIS SUPPURATIVA TRIAL

GlobeNewswire

December 8, 2025

EpiEndo Pharmaceutical's ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patients

GlobeNewswire

December 8, 2025

Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025

GlobeNewswire

December 8, 2025

Galapagos presenteerde nieuwe ATALANTA-1 celtherapiedata in MCL op ASH 2025

GlobeNewswire

December 8, 2025

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development

GlobeNewswire

December 8, 2025

OSE Immunotherapeutics annonce un amendement stratégique au partenariat avec AbbVie sur le développement d’ABBV-230

GlobeNewswire